Published 9 months ago • loading... • Updated 9 months ago
Eli Lilly loses appeal of $183.7 million Medicaid fraud award
Eli Lilly's decade-long pricing scheme concealed retroactive drug price increases, causing over $60 million underpayment to Medicaid, affirmed by the 7th Circuit Court.
A federal appeals court rejected Eli Lilly's appeal of a $183.7 million judgment for defrauding Medicaid by concealing retroactive price increases on drugs.
Lilly required wholesalers to pay more for drugs already purchased if prices increased, but reported original lower prices for Medicaid rebates.
The court said there was 'ample evidence' Lilly disregarded the risk of violating the law and obfuscated facts to deprive the government of over $60 million.